Kolexia
Guardiola Emmanuel Oncologie médicale
Guardiola Emmanuel
Oncologie médicale
Selarl Onco 34
Montpellier, France
64 Activités
163 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs de l'ovaire Tumeurs du sein Hypersensibilité Carcinome épithélial de l'ovaire Tumeurs des glandes endocrines Effets secondaires indésirables des médicaments Métastase tumorale Récidive tumorale locale Cellules tumorales circulantes

Collaborateurs

Voir plus
Lauche Olivier
Lauche Olivier
Oncoclem, Saint-Jean-de-Védas, France
Toledano Ivan
Toledano Ivan
Selarl Onco 34, Saint-Jean-de-Védas, France
Flandre Adrien
Flandre Adrien
Cabinet libéral, Montpellier, France
Villanueva Cristian
Villanueva Cristian
Oncoclem, Saint-Jean-de-Védas, France

Industries

Voir plus
Lilly
16 collaboration(s)
Dernière en 2023
Amgen
4 collaboration(s)
Dernière en 2022
MSD
3 collaboration(s)
Dernière en 2022
Sanofi
3 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
1st Line Treatment of Bevacizumab-Taxane vs Bevacizumab-Exemestane in Metastatic Breast Cancer: Phase III Randomized Multicenter Trial Comparing Continued Maintenance Therapy With the Bevacizumab + Taxane Versus Bevacizumab + Substituting Exemestane in Patients With Metastatic Breast Cancer or Locally Advanced With Estrogen Receptor Positive and Having at Least a Stable Disease After 16 to 18 Weeks of Treatment With Bevacizumab + Taxane.
Essai Clinique (ARCAGY/ GINECO GROUP)   05 septembre 2023
MITO16MANGO2b: Multicenter Phase III Randomized Study With Second Line Chemotherapy Plus or Minus Bevacizumab in Patients With Platinum Sensitive Epithelial Ovarian Cancer Recurrence After a Bevacizumab/Chemotherapy First Line
Essai Clinique (National Cancer Institute)   23 mars 2023
Association of COVID-19 Lockdown With the Tumor Burden in Patients With Newly Diagnosed Metastatic Colorectal Cancer.
JAMA network open   01 septembre 2021
Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial.
The Lancet. Oncology   18 février 2021
Trastuzumab versus observation for HER2 nonamplified early breast cancer with circulating tumor cells (EORTC 90091-10093, BIG 1-12, Treat CTC): a randomized phase II trial.
Annals of oncology : official journal of the European Society for Medical Oncology   23 décembre 2019
Decision of adjuvant chemotherapy in intermediate risk luminal breast cancer patients: A prospective multicenter trial assessing the clinical and psychological impact of EndoPredict® (EpClin) use (UCBG 2-14).
Breast (Edinburgh, Scotland)   14 novembre 2019
07 SEGAMED 2016 - Game design : Les propriétés du jeu comme point de départ
Youtube @ UFR médecine   13 janvier 2017
Phase II trial evaluating the combination of eribulin (E)+ bevacizumab (BEV) as first line chemotherapy in patients with metastatic Her2-negative breast cancer (MBC): a GINECO group study
Abstract Book of the 41st ESMO Congress (ESMO 2016), 7-11 October 2016, Copenhagen, Denmark   01 octobre 2016
A phase III trial of exemestane plus bevacizumab maintenance therapy in patients with metastatic breast cancer after first-line taxane and bevacizumab: a GINECO group study.
Annals of oncology : official journal of the European Society for Medical Oncology   24 février 2016
Encourage: the Use in Routine Practice of Bevacizumab in First-Line Therapy for Patients with Ovarian Cancer– a Gineco Prospective Cohort Study
Abstract Book of the 39th ESMO Congress (ESMO 2014) Madrid, Spain 26 – 30 September 2014   01 septembre 2014